Amylin Receptor Agonists
Cagrilintide
Late-stage human trialsInvestigational
Last reviewed: 2026-11-19
Evidence status & limitations
Large trials investigate this molecule alone and in combinations; results for a combination cannot be attributed entirely to cagrilintide.
Regulatory status
No FDA-approved human medicine for this exact identity was established in this review. Investigational research is not approval.
Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.
WADA prohibited status: current list and contextKnown risks & open questions
Gastrointestinal symptoms were reported in trials; rare and long-term risks require larger follow-up.
Key sources
Primary-reference and editorial check: November 19, 2026. Not an exhaustive clinical review; exact formulations and populations matter.